{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:15:14Z","timestamp":1794435314882,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Provincial Medical Science and Technology Research Fund Project","award":["A2024353"],"award-info":[{"award-number":["A2024353"]}]},{"name":"Shantou Medical Healthcare Science and Technology Program","award":["220519126490399"],"award-info":[{"award-number":["220519126490399"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-09490-1","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:09:02Z","timestamp":1751983742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment"],"prefix":"10.1038","volume":"15","author":[{"given":"Junchen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"9490_CR1","doi-asserted-by":"publisher","first-page":"1032103","DOI":"10.3389\/fneur.2022.1032103","volume":"13","author":"M Vincent","year":"2022","unstructured":"Vincent, M., Viktrup, L., Nicholson, R. A., Ossipov, M. H. & Vargas, B. B. The not so hidden impact of interictal burden in migraine: A narrative review. Front. Neurol. 13, 1032103 (2022).","journal-title":"Front. Neurol."},{"key":"9490_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/WCO.0000000000001267","volume":"37","author":"A Alpuente","year":"2024","unstructured":"Alpuente, A., Torres-Ferrus, M., Caronna, E. & Pozo-Rosich, P. The state of art on the use of patient reported outcomes in migraine. Curr. Opin. Neurol. 37, 271\u2013282 (2024).","journal-title":"Curr. Opin. Neurol."},{"key":"9490_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard, L. et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J. Headache Pain 21, 41 (2020).","journal-title":"J. Headache Pain"},{"key":"9490_CR4","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/head.14629","volume":"63","author":"RB Lipton","year":"2023","unstructured":"Lipton, R. B. et al. Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 63, 1448\u20131457 (2023).","journal-title":"Headache"},{"key":"9490_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro, R. E. et al. Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: Results of the OVERCOME (US) study. Neurology 102, e208074 (2024).","journal-title":"Neurology"},{"key":"9490_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker, B. et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol. Res. Perspect 8, e00567 (2020).","journal-title":"Pharmacol. Res. Perspect"},{"key":"9490_CR7","volume":"13","author":"A Datta","year":"2021","unstructured":"Datta, A., Maryala, S. & John, R. A review of eptinezumab use in migraine. Cureus 13, e18032 (2021).","journal-title":"Cureus"},{"issue":"55","key":"9490_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1358\/dot.2019.55.11.3069864","volume":"1998","author":"D Scuteri","year":"2019","unstructured":"Scuteri, D., Corasaniti, M. T., Tonin, P. & Bagetta, G. Eptinezumab for the treatment of migraine. Drugs Today (Barcelona, Spain) 1998(55), 695\u2013703 (2019).","journal-title":"Drugs Today (Barcelona, Spain)"},{"key":"9490_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick, D. W. et al. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache 60, 2220\u20132231 (2020).","journal-title":"Headache"},{"key":"9490_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow, D. et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial. BMC Neurol. 21, 126 (2021).","journal-title":"BMC Neurol."},{"key":"9490_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-021-01227-5","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith, T. R. et al. Safety and tolerability of eptinezumab in patients with migraine: A pooled analysis of 5 clinical trials. J. Headache Pain 22, 16 (2021).","journal-title":"J. Headache Pain"},{"key":"9490_CR12","first-page":"82","volume":"28","author":"Y Zhong","year":"2023","unstructured":"Zhong, Y. et al. Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis. J. Res. Med. Sci. 28, 82 (2023).","journal-title":"J. Res. Med. Sci."},{"key":"9490_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40120-023-00575-5","volume":"13","author":"P Pozo-Rosich","year":"2024","unstructured":"Pozo-Rosich, P. et al. Eptinezumab demonstrated efficacy regardless of prior preventive migraine treatment failure type: Post hoc analyses of the DELIVER study. Neurol. Ther. 13, 339\u2013353 (2024).","journal-title":"Neurol. Ther."},{"key":"9490_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","volume":"10","author":"HG Eichler","year":"2011","unstructured":"Eichler, H. G. et al. Bridging the efficacy-effectiveness gap: A regulator\u2019s perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 10, 495\u2013506 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9490_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2165\/11316550-000000000-00000","volume":"32","author":"TJ Giezen","year":"2009","unstructured":"Giezen, T. J., Mantel-Teeuwisse, A. K. & Leufkens, H. G. Pharmacovigilance of biopharmaceuticals: Challenges remain. Drug Saf. 32, 811\u2013817 (2009).","journal-title":"Drug Saf."},{"key":"9490_CR16","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner, P. K. et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: A randomized clinical trial. JAMA 325, 2348\u20132356 (2021).","journal-title":"JAMA"},{"key":"9490_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","volume":"19","author":"S Cecco","year":"2024","unstructured":"Cecco, S. et al. Emerging toxicities of antibody-drug conjugates for breast cancer: Clinical prioritization of adverse events from the FDA adverse event reporting system. Target. Oncol. 19, 435\u2013445 (2024).","journal-title":"Target. Oncol."},{"key":"9490_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40360-025-00894-3","volume":"26","author":"H Lin","year":"2025","unstructured":"Lin, H. et al. Post-market safety profile of cefiderocol: A real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS). BMC Pharmacol. Toxicol. 26, 58 (2025).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"9490_CR19","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","volume":"15","author":"K Zhao","year":"2024","unstructured":"Zhao, K., Zhao, Y., Xiao, S. & Tu, C. Assessing the real-world safety of tralokinumab for atopic dermatitis: Insights from a comprehensive analysis of FAERS data. Front. Pharmacol. 15, 1458438 (2024).","journal-title":"Front. Pharmacol."},{"key":"9490_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.858279","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Chen, C., Rong, C., He, X. & Chen, L. Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: A recent five-year pharmacovigilance study. Front. Pharmacol. 13, 858279 (2022).","journal-title":"Front. Pharmacol."},{"key":"9490_CR21","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin, Y., Shu, Y., Zhu, J., Li, F. & Li, J. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. Sci. Rep. 12, 19555 (2022).","journal-title":"Sci. Rep."},{"key":"9490_CR22","doi-asserted-by":"publisher","first-page":"1472648","DOI":"10.3389\/fphar.2024.1472648","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database. Front. Pharmacol. 15, 1472648 (2024).","journal-title":"Front. Pharmacol."},{"key":"9490_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Explanation and elaboration. Drug Saf. 47, 585\u2013599 (2024).","journal-title":"Drug Saf."},{"key":"9490_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine 59, 101967 (2023).","journal-title":"EClinicalMedicine"},{"key":"9490_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"9490_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"9490_CR27","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","volume":"95","author":"SA Rivkees","year":"2010","unstructured":"Rivkees, S. A. & Szarfman, A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J. Clin. Endocrinol. Metab. 95, 3260\u20133267 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"9490_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang, P. S., Chen, Z., Chan, C. L. & Tai, B. C. Data mining spontaneous adverse drug event reports for safety signals in Singapore - A comparison of three different disproportionality measures. Expert Opin. Drug Saf. 15, 583\u2013590 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"9490_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti, M., Antonazzo, I. C., Diemberger, I., De Ponti, F. & Raschi, E. Adverse events with sacubitril\/valsartan in the real world: Emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur. J. Prev. Cardiol. 28, 983\u2013989 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"9490_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","volume":"45","author":"C Gastaldon","year":"2022","unstructured":"Gastaldon, C. et al. Withdrawal syndrome following discontinuation of 28 antidepressants: Pharmacovigilance analysis of 31,688 reports from the who spontaneous reporting database. Drug Saf. 45, 1539\u20131549 (2022).","journal-title":"Drug Saf."},{"key":"9490_CR31","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"9490_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin. Res. ed.) 315, 629\u2013634 (1997).","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"9490_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s10194-024-01850-y","volume":"25","author":"YC An","year":"2024","unstructured":"An, Y. C. et al. Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population. J. Headache Pain 25, 149 (2024).","journal-title":"J. Headache Pain"},{"key":"9490_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/MNH.0000000000000447","volume":"27","author":"N Idzerda","year":"2018","unstructured":"Idzerda, N., Pena, M. J. & Heerspink, H. Personalized medicine in diabetic kidney disease: A novel approach to improve trial design and patient outcomes. Curr. Opin. Nephrol. Hypertens 27, 426\u2013432 (2018).","journal-title":"Curr. Opin. Nephrol. Hypertens"},{"key":"9490_CR35","doi-asserted-by":"publisher","first-page":"F29","DOI":"10.1152\/ajprenal.00125.2015","volume":"309","author":"J Schnermann","year":"2015","unstructured":"Schnermann, J. One physiology does not fit all: A path from data variability to \u201cphysiogenetics\u201d. Am. J. Physiol. Renal Physiol. 309, F29-32 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"9490_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.omtm.2020.06.006","volume":"18","author":"Y Ilan","year":"2020","unstructured":"Ilan, Y. Overcoming compensatory mechanisms toward chronic drug administration to ensure long-term, sustainable beneficial effects. Mol. Therapy Methods Clin. Dev. 18, 335\u2013344 (2020).","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"9490_CR37","doi-asserted-by":"publisher","first-page":"116385","DOI":"10.1016\/j.socscimed.2023.116385","volume":"339","author":"KM Lee","year":"2023","unstructured":"Lee, K. M. et al. A gender hypothesis of sex disparities in adverse drug events. Soc. Sci. Med. 339, 116385 (2023).","journal-title":"Soc. Sci. Med."},{"key":"9490_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14740338.2024.2337745","volume":"23","author":"AZA Meslamani","year":"2024","unstructured":"Meslamani, A. Z. A. Adverse drug event reporting among women: Uncovering disparities in underserved communities. Expert Opin. Drug Saf. 23, 543\u2013545 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"9490_CR39","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","volume":"4","author":"C Palleria","year":"2013","unstructured":"Palleria, C. et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two \u201cchallenging\u201d case reports. J. Pharmacol. Pharmacotherapeutics 4, S66\u2013S72 (2013).","journal-title":"J. Pharmacol. Pharmacotherapeutics"},{"issue":"13","key":"9490_CR40","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger, J. M. et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J. Clin. Oncol. 40(13), 1474\u20131486 (2022).","journal-title":"J. Clin. Oncol."},{"key":"9490_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton, R. B. et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68, 343\u2013349 (2007).","journal-title":"Neurology"},{"key":"9490_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1474-4422(16)30293-9","volume":"16","author":"KG Vetvik","year":"2017","unstructured":"Vetvik, K. G. & MacGregor, E. A. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 16, 76\u201387 (2017).","journal-title":"Lancet Neurol."},{"key":"9490_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex Differ. 11, 32 (2020).","journal-title":"Biol. Sex Differ."},{"key":"9490_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/pds.4155","volume":"26","author":"L Holm","year":"2017","unstructured":"Holm, L., Ekman, E. & Jors\u00e4terBlomgren, K. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol. Drug Saf. 26, 335\u2013343 (2017).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"9490_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/fcp.12032","volume":"28","author":"P D'Incau","year":"2014","unstructured":"D\u2019Incau, P. et al. No differences between men and women in adverse drug reactions related to psychotropic drugs: A survey from France, Italy and Spain. Fundam. Clin. Pharmacol. 28, 342\u2013348 (2014).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"9490_CR46","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1345\/aph.10218b","volume":"35","author":"BL Strom","year":"2001","unstructured":"Strom, B. L. Comment: Comparison of FDA reports of patient deaths associated with sildenafil and injectable alprostadil. Ann. Pharmacother. 35, 1143 (2001).","journal-title":"Ann. Pharmacother."},{"key":"9490_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni, A. A. & Jackson, S. H. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br. J. Clin. Pharmacol. 57, 6\u201314 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"9490_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cger.2012.01.007","volume":"28","author":"LC Sera","year":"2012","unstructured":"Sera, L. C. & McPherson, M. L. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin. Geriatr. Med. 28, 273\u2013286 (2012).","journal-title":"Clin. Geriatr. Med."},{"key":"9490_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117505","volume":"427","author":"AT Masoud","year":"2021","unstructured":"Masoud, A. T. et al. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. J. Neurol. Sci. 427, 117505 (2021).","journal-title":"J. Neurol. Sci."},{"key":"9490_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10194-022-01472-2","volume":"23","author":"X Wang","year":"2022","unstructured":"Wang, X., Wen, D., He, Q., You, C. & Ma, L. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J. Headache Pain 23, 105 (2022).","journal-title":"J. Headache Pain"},{"issue":"Suppl 1","key":"9490_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/head.13305","volume":"58","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson, L. The CGRP pathway in migraine as a viable target for therapies. Headache 58(Suppl 1), 33\u201347 (2018).","journal-title":"Headache"},{"key":"9490_CR52","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/ijms18081788","volume":"18","author":"AJ Sorby-Adams","year":"2017","unstructured":"Sorby-Adams, A. J., Marcoionni, A. M., Dempsey, E. R., Woenig, J. A. & Turner, R. J. The role of neurogenic inflammation in blood-brain barrier disruption and development of cerebral oedema following acute central nervous system (CNS) injury. Int. J. Mol. Sci. 18, 1788 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"9490_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11916-016-0578-4","volume":"20","author":"PL Durham","year":"2016","unstructured":"Durham, P. L. Diverse physiological roles of calcitonin gene-related peptide in migraine pathology: Modulation of neuronal-glial-immune cells to promote peripheral and central sensitization. Curr. Pain Headache Rep. 20, 48 (2016).","journal-title":"Curr. Pain Headache Rep."},{"key":"9490_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI182556","volume":"134","author":"JL Thomas","year":"2024","unstructured":"Thomas, J. L., Schindler, E. A. & Gottschalk, C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. J. Clin. Invest. 134, e182556 (2024).","journal-title":"J. Clin. Invest."},{"key":"9490_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140966","volume":"131","author":"NE Propson","year":"2021","unstructured":"Propson, N. E., Roy, E. R., Litvinchuk, A., K\u00f6hl, J. & Zheng, H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J. Clin. Invest. 131, e140966 (2021).","journal-title":"J. Clin. Invest."},{"key":"9490_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/1523-1747.ep12285627","volume":"108","author":"FE Fox","year":"1997","unstructured":"Fox, F. E. et al. Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: Effects on B7, interleukin 10, and interleukin 12. J. Invest. Dermatol. 108, 43\u201348 (1997).","journal-title":"J. Invest. Dermatol."},{"key":"9490_CR57","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1992.tb22832.x","volume":"657","author":"Y Umeda","year":"1992","unstructured":"Umeda, Y. Inhibition of immune responses by calcitonin gene-related peptide. Ann. N. Y. Acad. Sci. 657, 552\u2013554 (1992).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"9490_CR58","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00128-24","volume":"98","author":"CC Barbosa Bomfim","year":"2024","unstructured":"Barbosa Bomfim, C. C. et al. CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients. J. Virol. 98, e0012824 (2024).","journal-title":"J. Virol."},{"key":"9490_CR59","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/infdis\/jiad358","volume":"229","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Neuropeptide calcitonin gene-related peptide promotes immune homeostasis of bacterial meningitis by inducing major histocompatibility complex class II ubiquitination. J. Infect. Dis. 229, 855\u2013865 (2024).","journal-title":"J. Infect. Dis."},{"key":"9490_CR60","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. Under-reporting of adverse drug reactions: A systematic review. Drug Saf. 29, 385\u2013396 (2006).","journal-title":"Drug Saf."},{"key":"9490_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss, S. & Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 58, 323\u2013337 (2005).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09490-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T15:03:54Z","timestamp":1751987034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09490-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9490"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09490-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"24491"}}